Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases

Malignant Tumor of Pancreas Metastatic to Liver Clinical Trial

Official title:

A Randomized Open-Label Phase 2b Study of Hepatic Infusions of Anti-CEA CAR-T Cells Alternating With Systemic Chemotherapy Versus Chemotherapy Alone In Patients With Liver Metastases Due To CEA-Expressing Pancreatic Adenocarcinoma

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04037241
• Other study ID #: STI-CEA-201
• Status: Withdrawn
• Phase: Phase 2/Phase 3
• Start date: November 1, 2021
• Est. completion date: January 1, 2022

Study information

• Verified date: March 2022
• Source: Sorrento Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a randomized open-label phase 2b study of the efficacy and safety of regional infusion therapy with Anti-CEA CAR-T cells using the hepatic immunotherapy for metastases (HITM) method and the Trisalus pressure enabling drug delivery (PEDD) device alternating with systemic chemotherapy versus chemotherapy alone in patients with CEA-expressing pancreatic adenocarcinoma with liver metastases.

Description:

The study consists of 5 periods: Screening/Leukapheresis Period, Bridging Therapy Period, Randomization Period, Treatment Period, and Observation Period (which will be the long-term follow-up period to monitor for overall survival and long-term safety).

Patients in this trial with CEA-expressing pancreatic adenocarcinoma with liver metastases must have developed disease progression after first-line treatment with FOLFIRINOX (irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin) or gemcitabine-based chemotherapy. Patients will be randomized to either the "anti-CEA CAR-T Cells + systemic chemotherapy treatment arms", or the "chemotherapy alone treatment arms."

If the patients achieve at least stable disease during the Bridging Therapy Period, they will be in the Second-Line Group of Treatment Arms. Patients who develop disease progression during the Bridging Period will be in the Third-Line Group of Treatment Arms.

Patients in the Second-Line or Third-Line treatment arms who are randomized to the treatment arms of "Anti-CEA CAR-T cells plus systemic chemotherapy" will receive hepatic infusions of Anti-CEA CAR-T cells in Cycles 1 and 3 (ie, each 42-day cycle is 3 weekly doses of Anti-CEA CAR-T cells administered as hepatic arterial infusions using a PEDD device with low dose systemic IL-2 support), alternating with the systemic chemotherapy regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles >= 4. Systemic chemotherapy will be administered in 28-day cycles until the development of disease progression.

Patients in the Second-Line or Third-Line treatment arms who are randomized to the treatment arms "chemotherapy alone" arms will continue to receive the same systemic chemotherapy that they received during the Bridging Therapy Period. Systemic chemotherapy will be administered in 28-day or 21-day cycles (depending on the type of systemic chemotherapy regimen the patient will receive) until the development of disease progression.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 1, 2022
• Est. primary completion date: January 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have documented CEA-expressing pancreatic adenocarcinoma with unresectable liver metastases. Documentation of CEA-expressing adenocarcinoma may be demonstrated by an elevated serum CEA level (= 10 ng/mL) or by the detection of CEA on the cell surface of adenocarcino3.

• Documentation of disease progression of pancreatic adenocarcinoma following the initiation of first-line treatment with FOLFIRINOX or gemcitabine-based therapy.ma cells by immunohistochemistry (IHC).

• The primary pancreatic tumor may be intact and limited lung metastases (= 3 lesions, none > 1 cm in longest diameter) and lymphoid metastases (= 3 lesions, none > 1 cm in longest diameter) are permitted.

• There must be at least one measurable metastatic liver lesion ( = 10 mm in longest diameter).

• ECOG performance status of 0 or 1.

• Be willing and able to comply with the study schedule and all other protocol requirements.

• Females of childbearing potential must have 2 negative pregnancy tests prior to the start of study treatment, and must agree to pregnancy tests during the study; sexually active female and male patients must be willing to use an effective birth control to avoid pregnancy.

Exclusion Criteria:

• Received anti-cancer chemotherapy or investigational systemic anti-cancer treatments other than first line FOLFIRINOX or gemcitabine-based chemotherapy for advanced pancreatic adenocarcinoma.

• Received FOLFIRINOX or gemcitabine-based therapy within 14 days before receiving the first dose of study treatment.

• Have any unresolved toxicity > Grade 1 from previous anticancer therapy, except for stable chronic toxicities (= Grade 2) that are not expected to resolve.

• Have a history of histologically confirmed metastases outside the liver, lungs, or lymph nodes.

• More than 50% replacement of one or both hepatic lobes with tumor.

• Tumor causing biliary obstruction not amenable to stenting.

• Received prior anti-CEA agents, CAR-T, CAR-T cell line, CAR-NK, CAR-pNK, or CAR-NK cell line therapies.

• Have any clinically significant low baseline lab results for hemoglobin, platelet counts, or neutrophil counts at screening.

• Has any untreated or ongoing intra-abdominal infection or bowel obstruction.

• Has any clinically significant elevated baseline lab results for serum creatinine, aspartate aminotransferase (AST), and total bilirubin (except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome), and alkaline phosphatase at screening.

• Known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C.

• Female patients who are pregnant or breastfeeding.

• Has active bacterial, viral or fungal infections.

• Has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from participating in the study.

• Has any condition, including the presence of laboratory abnormalities that places the patient at an unacceptable risk if the patient was to participate in the study.

• Are receiving medications that are strong inducers CYP3A4 or CYP2C8 within 2 weeks of initiating treatment in the Bridging Therapy Period (rifampicin, carbamazepine, phenytoin, efavirenz, nevirapine, rifabutin, rifapentine, St. John's wort).

• Are receiving medications that inhibit CYP3A4 or CYP2C8 within 1 week of initiating treatment in the Bridging Therapy Period (ketoconazole and other imidazole antifungals, erythromycin, clarithromycin, itraconazole, voriconazole, fluoxetine, gemfibrozil, cimetidine, lopinavir, nefazodone, telaprevir, ritonavir, saquinavir, indinavir, or nelfinavir).

• Are receiving medications that inhibit UGT1A1 within 1 week of initiating nanoliposomal irinotecan therapy (atazanavir, gemfibrozil, indinavir).

• Left ventricular ejection fraction (LVEF) < 40%

Related Conditions & MeSH terms

• Malignant Tumor of Pancreas Metastatic to Liver
• Neoplasms
• Pancreatic Neoplasms

Intervention

Biological:
• Anti-CEA CAR-T cells
Doses will be delivered by hepatic arterial infusions using a pressure enabled drug delivery (PEDD) device

Drug:
• gemcitabine/nab paclitaxel
systemic chemotherapy regimen
• NLIR+FU/FA
systemic chemotherapy regimen
• Capecitabine
systemic chemotherapy regimen

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sorrento Therapeutics, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Assess if serum cytokine levels correlate with response and/or toxicity to hepatic arterial infusions	As an exploratory analysis, serum cytokine levels (pg/mL) will be measured over time by a standard laboratory test using Enzyme-linked immunosorbent assay (ELISA) to determine if increases in cytokines predict response and/or toxicity to liver arterial infusions.	6 - 12 months
Other	Assess if neutrophil: lymphocyte ratio (NLR) correlate with response from hepatic arterial infusions	As an exploratory analysis, NLR will be calculated to determine if there is a correlation with response and/or toxicity.	6 - 12 months
Other	Assess the persistence of CAR-T cells in liver tumor biopsies over time.	As an exploratory analysis, the engraftment of CAR-T cells in planned liver tumor biopsies will be analyzed to assess persistence of CAR-T cells during the Treatment and Observation Periods of the study.	6 - 12 months
Primary	Assess efficacy by overall survival	As a measure of activity, Overall Survival (OS) will be assessed. The events for the assessment of OS are death events. Time to event endpoints will be estimated using Kaplan-Meier methods. Point estimates and 95% confidence intervals will be provided where applicable.	6 - 12 months
Secondary	Assess safety by monitoring adverse events	As a measure of safety, the types, frequencies, and severities of adverse events and their relationship to study drug will be summarized.	6 - 12 months
Secondary	Assess efficacy by within-liver progression free survival (PFS)	As a measure of activity, within-liver PFS will be assessed. The events for the assessment of within-liver PFS will be measured from the date of randomization to the date of disease progression within the liver or death, whichever comes first. This time to event endpoint will be estimated using Kaplan-Meier methods. Point estimates and 95% confidence intervals will be provided where appropriate.	6 - 12 months
Secondary	Assess efficacy by progression free survival (PFS)	As a measure of activity, PFS will be assessed. The events for the assessment of PFS will be measured from the date of randomization to the date of disease progression or death, whichever comes first. This time to event endpoint will be estimated using Kaplan-Meier methods. Point estimates and 95% confidence intervals will be provided where appropriate.	6 - 12 months
Secondary	Assess efficacy by within-liver time to progression (TTP)	As a measure of activity, within-liver TTP will be assessed. The events for the assessment of within-liver TTP will be measured from the date of randomization to the date of disease progression within the liver. This time to event endpoint will be estimated using Kaplan-Meier methods. Point estimates and 95% confidence intervals will be provided where appropriate.	6 - 12 months
Secondary	Assess efficacy by time to progression (TTP)	As a measure of activity, TTP will be assessed. The events for the assessment of TTP will be measured from the date of randomization to the date of disease progression. This time to event endpoint will be estimated using Kaplan-Meier methods. Point estimates and 95% confidence intervals will be provided where appropriate.	6 - 12 months
Secondary	Assess efficacy by within-liver radiographic response rate using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)	As a measure of activity, overall response rate within-liver will be assessed using radiographic scans using RECIST v 1.1 criteria. Response will be assessed for each patient over a 6- to 12-month timeframe during the Treatment and Observation Periods of the protocol.	6 - 12 months
Secondary	Assess efficacy by overall whole-body radiographic response rate using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)	As a measure of activity, overall response rate for overall whole-body will be assessed using radiographic scans using RECIST v 1.1 criteria. Response will be assessed for each patient over a 6- to 12-month timeframe during the Treatment and Observation Periods of the protocol.	6 - 12 months
Secondary	Assess efficacy by duration of response within-liver in accordance with RECIST v 1.1 criteria	As a measure of activity, duration of response within-liver will be measured using radiologic scans and assessed according to RECIST v1.1 criteria. This will be assessed for each patient over a 6- to 12-month timeframe during the Treatment and Observation Periods of the protocol.	6 - 12 months
Secondary	Assess efficacy by duration of response of overall whole-body in accordance with RECIST v 1.1 criteria	As a measure of activity, duration of response of overall whole-body will be measured using radiologic scans and assessed according to RECIST v1.1 criteria. This will be assessed for each patient over a 6- to 12-month timeframe during the Treatment and Observation Periods of the protocol.	6 - 12 months
Secondary	Assess efficacy by serologic response rates by CEA levels	As a measure of activity, overall response rate will be assessed by serologic CEA levels. Response rate will be assessed for each patient over a 6- to 12-month timeframe during the Treatment and Observation Periods of the protocol.	6 - 12 months
Secondary	Assess efficacy by serologic response rates by CA 19-9 levels	As a measure of activity, overall response rate will be assessed by serologic CA 19-9 levels. Response rate will be assessed for each patient over a 6- to 12-month timeframe during the Treatment and Observation Periods of the protocol.	6 - 12 months
Secondary	Evaluation of Quality-of-Life using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)	As a measure of quality-of-life, the EORTC QLQ-C30 instrument will be administered at months 2, 4, 6 of the Treatment Period and at the end of study.	6 - 12 months
Secondary	Evaluation of Quality-of-Life using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Pancreatic Cancer Module (EORTC QLQ-PAN26)	As a measure of quality-of-life specific for patients with pancreatic cancer, the EORTC QLQ-PAN26 instrument will be administered at months 2, 4, 6 of the Treatment Period and at the end of study.	6 - 12 months
Secondary	Evaluation of Quality-of-Life using the 5-level EQ-5D version (EQ-5D-5L) questionnaire	As a measure of quality-of-life, the EQ-5D-5L questionnaire will be administered at months 2, 4, 6 of the Treatment Period and at the end of study.	6 - 12 months